The Promise of Epigenomic Therapeutics in Pancreatic Cancer

Overview

Journal Epigenomics

Specialty Genetics

Date 2016 Jun 24

PMID 27337224

Citations 27

Authors

Gwen A Lomberk

Juan Iovanna

Raul Urrutia

Affiliations

Soon will be listed here.

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is often viewed to arise primarily by genetic alterations. However, today we know that many aspects of the cancer phenotype require a crosstalk among these genetic alterations with epigenetic changes. Indeed, aberrant gene expression patterns, driven by epigenetics are fixed by altered signaling from mutated oncogenes and tumor suppressors to define the PDAC phenotype. This conceptual framework may have significant mechanistic value and could offer novel possibilities for treating patients affected with PDAC. In fact, extensive investigations are leading to the development of small molecule drugs that reversibly modify the epigenome. These new 'epigenetic therapeutics' discussed herein are promising to fuel a new era of studies, by providing the medical community with new tools to treat this dismal disease.

Citing Articles

Spatial recognition and semi-quantification of epigenetic events in pancreatic cancer subtypes with multiplexed molecular imaging and machine learning.

Szymonski K, Janiszewska N, Sofinska K, Skirlinska-Nosek K, Lupa D, Czaja M Sci Rep. 2025; 15(1):6518.

PMID: 39987295 PMC: 11846859. DOI: 10.1038/s41598-025-90087-z.

The role of epigenetic regulation in pancreatic ductal adenocarcinoma progression and drug response: an integrative genomic and pharmacological prognostic prediction model.

Fu K, Su J, Zhou Y, Chen X, Hu X Front Pharmacol. 2024; 15:1498031.

PMID: 39640482 PMC: 11618540. DOI: 10.3389/fphar.2024.1498031.

The triple code model for advancing research in rare and undiagnosed diseases beyond the base pairs.

Lomberk G, Urrutia R Epigenomics. 2024; 17(2):115-124.

PMID: 39630027 PMC: 11792834. DOI: 10.1080/17501911.2024.2436837.

Deep representation learning of chemical-induced transcriptional profile for phenotype-based drug discovery.

Tong X, Qu N, Kong X, Ni S, Zhou J, Wang K Nat Commun. 2024; 15(1):5378.

PMID: 38918369 PMC: 11199551. DOI: 10.1038/s41467-024-49620-3.

The Impact of Oxidative Stress on the Epigenetics of Fetal Alcohol Spectrum Disorders.

Terracina S, Tarani L, Ceccanti M, Vitali M, Francati S, Lucarelli M Antioxidants (Basel). 2024; 13(4).

PMID: 38671857 PMC: 11047541. DOI: 10.3390/antiox13040410.

References

Feinberg A, Tycko B . The history of cancer epigenetics. Nat Rev Cancer. 2004; 4(2):143-53. DOI: 10.1038/nrc1279. View

Blasco F, Penuelas S, Cascallo M, Hernandez J, Alemany C, Masa M . Expression profiles of a human pancreatic cancer cell line upon induction of apoptosis search for modulators in cancer therapy. Oncology. 2004; 67(3-4):277-90. DOI: 10.1159/000081329. View

Farria A, Li W, Dent S . KATs in cancer: functions and therapies. Oncogene. 2015; 34(38):4901-13. PMC: 4530097. DOI: 10.1038/onc.2014.453. View

Adams D, Altucci L, Antonarakis S, Ballesteros J, Beck S, Bird A . BLUEPRINT to decode the epigenetic signature written in blood. Nat Biotechnol. 2012; 30(3):224-6. DOI: 10.1038/nbt.2153. View

Filippakopoulos P, Knapp S . Targeting bromodomains: epigenetic readers of lysine acetylation. Nat Rev Drug Discov. 2014; 13(5):337-56. DOI: 10.1038/nrd4286. View

Rotili D, Mai A . Targeting Histone Demethylases: A New Avenue for the Fight against Cancer. Genes Cancer. 2011; 2(6):663-79. PMC: 3174264. DOI: 10.1177/1947601911417976. View

Seligson D, Horvath S, McBrian M, Mah V, Yu H, Tze S . Global levels of histone modifications predict prognosis in different cancers. Am J Pathol. 2009; 174(5):1619-28. PMC: 2671251. DOI: 10.2353/ajpath.2009.080874. View

Ueki T, Toyota M, Sohn T, Yeo C, Issa J, Hruban R . Hypermethylation of multiple genes in pancreatic adenocarcinoma. Cancer Res. 2000; 60(7):1835-9. View

Mazur P, Herner A, Mello S, Wirth M, Hausmann S, Sanchez-Rivera F . Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. Nat Med. 2015; 21(10):1163-71. PMC: 4959788. DOI: 10.1038/nm.3952. View

10.

Barneda-Zahonero B, Parra M . Histone deacetylases and cancer. Mol Oncol. 2012; 6(6):579-89. PMC: 5528343. DOI: 10.1016/j.molonc.2012.07.003. View

11.

Subramaniam D, Thombre R, Dhar A, Anant S . DNA methyltransferases: a novel target for prevention and therapy. Front Oncol. 2014; 4:80. PMC: 4013461. DOI: 10.3389/fonc.2014.00080. View

12.

Bloomston M, Frankel W, Petrocca F, Volinia S, Alder H, Hagan J . MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA. 2007; 297(17):1901-8. DOI: 10.1001/jama.297.17.1901. View

13.

McCleary-Wheeler A, Lomberk G, Weiss F, Schneider G, Fabbri M, Poshusta T . Insights into the epigenetic mechanisms controlling pancreatic carcinogenesis. Cancer Lett. 2012; 328(2):212-21. PMC: 3513548. DOI: 10.1016/j.canlet.2012.10.005. View

14.

Yun M, Wu J, Workman J, Li B . Readers of histone modifications. Cell Res. 2011; 21(4):564-78. PMC: 3131977. DOI: 10.1038/cr.2011.42. View

15.

Marsoni S, Damia G, Camboni G . A work in progress: the clinical development of histone deacetylase inhibitors. Epigenetics. 2008; 3(3):164-71. DOI: 10.4161/epi.3.3.6253. View

16.

Lomberk G, Mathison A, Grzenda A, Urrutia R . The sunset of somatic genetics and the dawn of epigenetics: a new frontier in pancreatic cancer research. Curr Opin Gastroenterol. 2009; 24(5):597-602. PMC: 2941574. DOI: 10.1097/MOG.0b013e32830b111d. View

17.

Goll M, Bestor T . Eukaryotic cytosine methyltransferases. Annu Rev Biochem. 2005; 74:481-514. DOI: 10.1146/annurev.biochem.74.010904.153721. View

18.

Filipowicz W, Bhattacharyya S, Sonenberg N . Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?. Nat Rev Genet. 2008; 9(2):102-14. DOI: 10.1038/nrg2290. View

19.

Li Z, Rana T . Therapeutic targeting of microRNAs: current status and future challenges. Nat Rev Drug Discov. 2014; 13(8):622-38. DOI: 10.1038/nrd4359. View

20.

Strahl B, Allis C . The language of covalent histone modifications. Nature. 2000; 403(6765):41-5. DOI: 10.1038/47412. View